Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution

American Journal of Cardiology

Volumn 84, Issue 4, 1999, Pages 404-409

  Feldman, Mark ^a   Cryer, Byron ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BUFFER; PLACEBO; SALICYLIC ACID; THROMBOXANE B2;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWALLOWING; TABLET; THROMBOCYTE AGGREGATION INHIBITION; VOLUNTEER;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ASPIRIN; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRATES; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUGS, NON-PRESCRIPTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASTICATION; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; SODIUM BICARBONATE; THROMBOXANE B2;

EID: 0033566859     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00324-0     Document Type: Article

References (15)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
2. Fuster V., Dyken M.L., Vokonas P.S., Hennekins C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 87:1993;659-675.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. 2:1988;349-360.
4. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis D., Hiratzka L.F., Rapaport E., Riegel B.J., Russell R.O., Smith E.E., Weaver W.D. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on management of acute myocardial infarction). J Am Coll Cardiol. 28:1996;1328-1419.
5. Berger PB. Acute Myocardial Infarction. sec. 1. chap. VIII. In: Dale DC, ed. New York: Scientific American Inc., 1998:1-27.
6. Antman E.M., Braunwald E. Acute myocardial infarction. Fauci A.S., Braunwald E., Isselbacher K.J. Harrison's Principles of Internal Medicine. 14th ed. 1998;1352-1365 McGraw-Hill, New York.
7. Kees F., Jehnich D., Grobecker H. Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 677:1996;172-177.
8. Lee M., Cryer B., Feldman M. Dose-effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med. 120:1994;184-189.
9. Sharis P.J., Cannon C.P., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 129:1998;394-405.
10. Dromgoole SH, Furst DE. Salicylates. In: WE Evans, JJ Schentag, WJ Jusko, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc., 1994:32-1, 32-34.
11. Pedersen A.K., Fitzgerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 311:1984;1206-1211.
12. 2 . J Pharmacol Exp Ther. 259:1991;1043-1049.
13. Jimenez A.H., Stubbs M.E., Tofler G.H., Winther K., Williams G.H., Muller J.E. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol. 69:1992;258-262.
14. Lange R.A., Hillis L.D. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis - the preferred treatment. N Engl J Med. 335:1996;1311-1312.
15. Anderson H.V., Willerson J.T. Thrombolysis in acute myocardial infarction. N Engl J Med. 329:1993;703-709.